EUVIMEDEUVIMED entdecken
Crossref

Intralesional Bleomycin injections of cystic hygromas in pediatric patients

Sarah Arafat, Moutaz Ragab, Gamal El-Tagy

Journal of Cranio-Maxillofacial Surgery · 2026

DOI: 10.1016/j.jcms.2026.109846 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cranio-Maxillofacial Surgery, 2026. Verfasst von Sarah Arafat und 2 weiteren Autor:innen. Beteiligte Einrichtung: Oral and Maxillofacial Surgery, Faculty of Oral and Dental Medicine, Delta University for Science and Technology, Al Mansurah, Egypt. Electronic addr…. Hauptthemen laut MEDLINE: Bleomycin, Lymphangioma, Cystic, Antibiotics, Antineoplastic, Sclerosing Solutions. Die Arbeit nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Cystic hygromas are congenital macrocystic lymphatic malformations. Most cystic hygromas present at birth, during infancy or early childhood. Sclerotherapy is the main treatment, and Bleomycin is the most frequently used sclerosing agent. OBJECTIVES: To evaluate if intralesional Bleomycin (BLM) injection is a safe and effective treatment of cystic hygromas in pediatric patients. STUDY DESIGN: retrospective cohort study. PATIENTS AND METHODS: This case series includes 30 pediatric patients who had cystic hygromas and underwent intralesional Bleomycin injections. INTERVENTIONS: The cystic lymphatic fluid was aspirated from each cystic hygroma, and then the lesion was simultaneously injected with Bleomycin during the first treatment session, then, the lesions were injected at 4-week intervals until satisfactory results were obtained. The Bleomycin 15 IU vial was freshly prepared on each session; 15 mg powdered BLM was dissolved in 15 mL of 0/9% normal saline (1 IU BLM equals 1 mg/mL BLM), with 0.5 IU/kg body weight safe pediatric dose; and 15 IU/session maximum dose. Clinical response was assessed as complete response (>90% reduction of lesion size), marked improvement (>70%), moderate improvement (50 - 70%), slight improvement (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BleomycinLymphangioma, CysticAntibiotics, AntineoplasticSclerosing SolutionsHumansInjections, IntralesionalFemaleMaleRetrospective StudiesChild, PreschoolInfantTreatment OutcomeSclerotherapyChild

Stichwörter der Autor:innen

BleomycinCystic hygromaIntralesionalPediatric

Substanzen

BleomycinAntibiotics, AntineoplasticSclerosing Solutions

Autor:innen und Institutionen

  • Oral and Maxillofacial Surgery, Faculty of Oral and Dental Medicine, Delta University for Science and Technology, Al Mansurah, Egypt. Electronic address: sarah2000arafat@gmail.com.
  • Pediatric Surgery, Cairo University Specialized Pediatric Hospital (CUSPH), Faculty of Medicine, Cairo University, Cairo, Egypt. Electronic address: moutazragab86@gmail.com.
  • Pediatric Surgery, Cairo University Specialized Pediatric Hospital (CUSPH), Faculty of Medicine, Cairo University, Cairo, Egypt. Electronic address: eltagy@gmail.com.

Zitieren

APA

Arafat, S., Ragab, M., & El-Tagy, G. (2026). Intralesional Bleomycin injections of cystic hygromas in pediatric patients. Journal of Cranio-Maxillofacial Surgery. https://doi.org/10.1016/j.jcms.2026.109846

Vancouver

Arafat S, Ragab M, El-Tagy G. Intralesional Bleomycin injections of cystic hygromas in pediatric patients. Journal of Cranio-Maxillofacial Surgery. 2026. doi:10.1016/j.jcms.2026.109846

BibTeX
@article{Arafat2026,
  author = {Arafat, Sarah and Ragab, Moutaz and El-Tagy, Gamal},
  title = {Intralesional Bleomycin injections of cystic hygromas in pediatric patients},
  journal = {Journal of Cranio-Maxillofacial Surgery},
  year = {2026},
  doi = {10.1016/j.jcms.2026.109846}
}
Kostenlos starten →